Camilla Sandberg

Chief Executive Officer at MIRIS HOLDING AB

57 year

Health Technology

Electronic Technology

Consumer Services

Profile

Camilla Myhre Sandberg is currently the Chief Executive Officer at Miris Holding AB since 2016.
She is also an Independent Director at Monivent AB and NextCell Pharma AB.
Previously, she worked as the Vice President-Sales & Marketing at BioLamina AB.
Ms. Sandberg completed her undergraduate degree in 1996 and MBA in 1998 from the University of Oslo.

Camilla Sandberg active positions

Companies	Position	Start
MIRIS HOLDING AB	Chief Executive Officer	03/10/2016
NEXTCELL PHARMA AB	Director/Board Member	31/12/2016
MONIVENT AB	Director/Board Member	-

All active positions of Camilla Sandberg

Former positions of Camilla Sandberg

Companies	Position	End
BioLamina AB BioLamina AB BiotechnologyHealth Technology BioLamina AB develops, manufactures and markets cell culture reagents intended for culturing of primary cells. Its applications animal stem cells, cancer cells, cardiac applications, clonal applications, endothelial applications, epithelial applications, expansion of human PSC, eye applications, hepatic applications, intestinal applications, kidney cell culture, lung applications, neural applications, pancreatic applications and skeletal muscle applications. The company was founded by Kristian Tryggvason and Karl Tryggvason in 2008 and is headquartered in Sundbyberg, Sweden.	Sales & Marketing	-

See the detail of Camilla Sandberg's experience

Training of Camilla Sandberg

University of Oslo

Masters Business Admin

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Camilla Sandberg's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	3
MIRIS HOLDING AB	Electronic Technology
MONIVENT AB	Health Technology
NEXTCELL PHARMA AB	Health Technology

Private companies	1
BioLamina AB BioLamina AB BiotechnologyHealth Technology BioLamina AB develops, manufactures and markets cell culture reagents intended for culturing of primary cells. Its applications animal stem cells, cancer cells, cardiac applications, clonal applications, endothelial applications, epithelial applications, expansion of human PSC, eye applications, hepatic applications, intestinal applications, kidney cell culture, lung applications, neural applications, pancreatic applications and skeletal muscle applications. The company was founded by Kristian Tryggvason and Karl Tryggvason in 2008 and is headquartered in Sundbyberg, Sweden.	Health Technology